Tokyo, Japan and Cambridge, UK, 12 May 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) notes that its partner PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”; TOKYO: 4587) announced today the achievement of an important milestone in its ongoing collaboration with the Company to discover, develop and commercialize novel peptide therapeutics targeting PAR2, a G protein-coupled receptor (GPCR) with an important role in inflammatory diseases and pain. The full announcement from PeptiDream is available here.
As per the terms of the agreement, Sosei and PeptiDream jointly conduct and share the costs of the discovery and development program and will co-own any resulting products.
Miles Congreve, Sosei Heptares Chief Scientific Officer, said: “The development of peptide therapeutics for delivery via an oral route can be challenging, given the gut is extremely efficient at breaking such molecules down. For PAR2, by designing peptide leads that are stable in the gut environment, Sosei Heptares and PeptiDream have overcome a potential challenge and limiting factor for therapeutic development of a peptide for this target.”